Galecto, Inc. (GLTO): Aggregate Business Value

Galecto Corporation - graphic logo of issuer GLTO

This Galecto, Inc. (GLTO) price chart on GURU.Markets illustrating value trends shows an Enterprise Value of 1722.09. The decline in share price was driven by the failure of the lead drug candidate in Phase II trials, which deterred institutional investors. However, Galecto, Inc. (GLTO) relies on automated compound synthesis to accelerate development and the potential for selective protein targeting in tissue scarring, providing the company with significant pricing power.

GLTO (galecto.com) Total Company Value history from 11/23/2025 to 03/10/2026

Galecto, Inc. (GLTO) - metric breakdowns and financial figures

- price and consensus price forecast:
Price Chart Galecto Inc|GLTO - Consensus Target
- market capitalization data:
Market Value Galecto|GLTO - Total Company Value
- book capitalization data:
Net Asset Value per Share Galecto|GLTO - Company Book Value|Market Capitalization to Net Assets galecto.com|GLTO - Company Total Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio Galecto, Inc.|GLTO - Long-Term Debt to Capital|Short-Term Debt to Capital galecto.com|GLTO - Company Debts|Debt to Net Assets Ratio Galecto
Comprehensive company analysis:Galecto Inc (GLTO)
Original product of Galecto, Inc.

This indicator synthesizes market capitalization and net debt to determine the actual cost of a full asset buyout, accounting for all liabilities and liquidity. By analyzing the enterprise value metric, an investor assesses the valuation of Galecto, Inc. (GLTO) through the lens of its anti-fibrosis pipeline diversification, where the company's real price reflects market demand for the potential of several independent clinical trials.

Competitor analysis for Galecto, Inc.

ASND - Total Company Value|Real Price to Acquire Entire Company Madrigal Pharma MDGL|CORT: Aggregate Business Value|Total Company Value RYTM|AKRO (akerotx.com) - Total Enterprise Value|Total Company Value Metsera MTSR|Full Business Value MoonLake Immunotherapeutics AG|Crinetics Pharma (CRNX) - Enterprise Value|Value Adjusted for Debt and Cash NewAmsterdam Pharma Corp (NAMS)|Enterprise Value SLNO (Soleno Therapeutics)|amicusrx.com - Enterprise Value|Total Company Value 89bio (ETNB)|AGIO: Value Adjusted for Debt and Cash|GPCR (Structure Pharma) - Total Company Value|MiMedx Corp (MDXG) - Real Price to Acquire Entire Company|RZLT (Rezolute, Inc.) - Enterprise Value|Enterprise Value lexpharma.com (LXRX)|MBX Biosciences (MBX) - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash ALT (Altimmune Inc)|Aardvark Therapeutics Corp - Total Company Value|Real Price to Acquire Entire Company Sagimet Biosciences Inc SGMT|BIOA (BioAge Labs, Inc.) - Enterprise Value|biomeafusion.com (BMEA) - Total Enterprise Value|QNCX - Real Price to Acquire Entire Company|Fractyl Health Inc. (GUTS) - Aggregate Business Value|VTVT (vTv Therapeutics, Inc.) - Enterprise Value|Enterprise Value Agape ATP Corp.|Enterprise Value Pluri Inc. (PLUR)|Total Company Value SYBX (synlogictx.com)|LPCN: Total Company Value|Matinas BioPharma Holdings, Inc. - Total Enterprise Value|SPRB - Total Company Value|CTCX - Total Company Value|Lumos Pharma, Inc. - Enterprise Value|ONVO (organovo.com) - Company Buyout Price|RDUS: Total Company Value